Physician profile
Kevin Solis
NPI 1538362116
$1,877.94
in general payments reported to CMS, 2019-2025
10 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.27 · 2020: $312 · 2021: $285 · 2022: $71.37 · 2023: $253 · 2024: $490 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $526.10 | 2019-2021 | |
| Alcon Vision LLC | $446.05 | 2019-2025 | Wavelight Ex500 Excimer Laser, Dailies Total1, Clareon |
| Glaukos Corporation | $181.34 | 2025 | Kxl System (Not Refurbished) |
| Coopervision INC. | $181.14 | 2024 | Ortho-K Contact Lens, Onefit Contact Lens, Paragon Crt |
| Visioneering Technologies, INC. | $171.39 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $117.09 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $103.94 | 2022-2025 | Infuse |
| Oyster Point Pharma, INC. | $103.35 | 2024 | Tyrvaya |
| Dompe US, INC. | $33.17 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $14.37 | 2023 | Cequa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.